The latest scientific articles, laboratory findings, and quality assurance documentation for nojine biological products.
A scientific step toward bridging academic research and advanced industrial production technology in the country.
A landmark memorandum of understanding for joint biotechnology research and development of specialized immunoglobulin formulations was officially signed.
Periodic regulatory and healthcare audits concluded with outstanding scores and zero deviations, affirming Nojin's commitment to world-class aseptic manufacturing.
Presentation of three prominent research papers regarding efficacy optimization of Albojin in intensive care units received accolades from international scientific panels.
Ensuring uncompromising 2°C to 8°C thermal stability from production lines to nationwide clinical centers via real-time GPS telemetry and cloud logging.
Following rigorous biological and technical evaluations, Nojin's advanced human plasma fractionation line was officially inaugurated, marking a transformative leap in biological therapeutics self-sufficiency.
nojin Zist Pharmed's pharmaceutical portfolio is developing new clinical treatment options in line with maximizing the coverage of the country's therapeutic needs.
Compliance with Good Manufacturing Practice (GMP) legal requirements in the storage and distribution sector guarantees maintaining the safety and efficacy of biological products.
Achieving technological independence in the human blood plasma fractionation chain is one of the country's strategic goals in the field of pharmaceutical biotechnology. In this scientific monograph, we review the achievements of nojin's R&D department in localizing advanced membrane separation methods.
There is currently no active research in this category. New scientific findings will be uploaded in this section after final approval by the editorial board.
Committed to supplying biological therapeutics and plasma-derived products with the highest global quality standards.